Matrix metalloproteinases and matrikines in angiogenesis

被引:79
|
作者
Bellon, G
Martiny, L
Robinet, A
机构
[1] Univ Reims, Fac Med, IFR 53 Biomol, CNRS,FRE 2534,Lab Biochem & Mol Biol, F-51095 Reims, France
[2] Univ Reims, Fac Sci, CNRS, FRE 2534,Lab Biochem, F-51095 Reims, France
关键词
angiogenesis; tumor growth and metastasis; matrix metalloproteinase; extracellular matrix; matrikine;
D O I
10.1016/j.critrevonc.2003.10.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neoangiogenesis, the formation of new blood capillaries from pre-existing vessels, plays an important role in a number of physiological and pathological processes, particularly in tumor growth and metastasis. Extracellular proteolysis by matrix metalloproteinases or other neutral proteinases is an absolute requirement for initiating tumor invasion and angiogenesis. Cryptic segments or pre-existing domains within larger proteins, most of them belonging to the extracellular matrix, can be exposed by conformational changes and/or generated by partial enzymatic hydrolysis. They can positively or negatively regulate important functions of endothelial cells including adhesion, migration, proliferation, cell survival and cell-cell interactions. Such regulations by cryptic segments and proteolytic fragments led to the concept of matricryptins and matrikines, respectively. Matrix metalloproteinases and matrikines in conjunction with other pro- or anti-angiogenic factors might act in concert at any step of the angiogenesis process. A number of matrikines have been identified as potent anti-angiogenic factors, which could provide a new alternative to anti-proteolytic strategies for the development of anti-angiogenic therapeutic molecules aimed at inhibiting tumor growth and metastasis. Some of them are currently being investigated in clinical trials. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:203 / 220
页数:18
相关论文
共 50 条
  • [41] Metalloproteinases and their inhibitors in tumor angiogenesis
    Handsley, MM
    Edwards, DR
    INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (06) : 849 - 860
  • [42] Matrix metalloproteinases
    Nagase, H
    Woessner, JF
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (31) : 21491 - 21494
  • [43] Matrix Metalloproteinases
    Zitka, O.
    Kukacka, J.
    Krizkova, S.
    Huska, D.
    Adam, V.
    Masarik, M.
    Prusa, R.
    Kizek, R.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (31) : 3751 - 3768
  • [44] Matrix metalloproteinases
    Matrisian, LM
    CURRENT BIOLOGY, 2000, 10 (19) : R692 - R692
  • [45] Matrix metalloproteinases
    Roy, MK
    Carey, PD
    BRITISH JOURNAL OF SURGERY, 1997, 84 (08) : 1171 - 1171
  • [46] Matrix metalloproteinases
    Johnson, LL
    Dyer, R
    Hupe, DJ
    CURRENT OPINION IN CHEMICAL BIOLOGY, 1998, 2 (04) : 466 - 471
  • [47] Matrix metalloproteinases
    Parsons, SL
    Watson, SA
    Brown, PD
    Collins, HM
    Steele, RJC
    BRITISH JOURNAL OF SURGERY, 1997, 84 (02) : 160 - 166
  • [48] Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
    Borden, P
    Heller, RA
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1997, 7 (1-2): : 159 - 178
  • [49] Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease
    Zakiyanov, Oskar
    Kalousova, Marta
    Zima, Tomas
    Tesar, Vladimir
    ADVANCES IN CLINICAL CHEMISTRY, VOL 105, 2021, 105 : 141 - 212
  • [50] Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases
    Kondo, S
    Kubota, S
    Shimo, T
    Nishida, T
    Yosimichi, G
    Eguchi, T
    Sugahara, T
    Takigawa, M
    CARCINOGENESIS, 2002, 23 (05) : 769 - 776